炎症性肠病患者急性髓系白血病与骨髓增生异常综合征发病率及硫嘌呤暴露的影响
该回顾性队列研究基于退伍军人事务数据集的56,314例炎症性肠病患者,评估硫嘌呤暴露与急性髓系白血病/骨髓增生异常综合征(AML/MDS)风险的关系。总体发病率为18.7/10万患者年,当前使用硫嘌呤与AML/MDS风险增加相关,而既往使用者风险未增加。
要点
- IBD患者中AML/MDS总体发病率为18.7/10万患者年。
- 当前使用硫嘌呤(累积暴露<2年)与AML/MDS风险增加相关(aHR 3.05)。
- 当前使用硫嘌呤(累积暴露≥2年)风险亦增加(aHR 2.32),停药后风险回落至基线。
核心结论
- 在IBD患者中,当前使用硫嘌呤与AML/MDS风险增加相关,停药后风险恢复至基线水平。
研究设计与样本
- 回顾性队列研究,纳入退伍军人事务数据集中的56,314例IBD患者,按硫嘌呤暴露状态分组,采用Cox回归估计风险比。
主要发现
- 107例患者发生AML/MDS,总体发病率为18.7/10万患者年。
- 从未暴露、既往暴露、当前暴露累积<2年、当前暴露累积≥2年的发病率分别为17.0、17.7、30.4、30.3/10万患者年。
- 多因素Cox回归显示,与从未暴露相比,当前使用硫嘌呤累积<2年的aHR为3.05(95%CI 1.54-6.06,P=0.0014),累积≥2年的aHR为2.32(95%CI 1.22-4.41,P=0.0101)。
- 既往硫嘌呤暴露与AML/MDS风险无显著关联。
关键数值与推荐
- 硫嘌呤暴露定义:从未暴露、既往暴露(停药>6个月)、当前暴露累积<2年、当前暴露累积≥2年。
- 结局为AML和/或MDS的复合终点。
临床怎么用
- 临床医生在为IBD患者处方硫嘌呤时,应权衡AML/MDS风险,尤其对于当前使用且累积暴露<2年的患者。
- 对于既往使用硫嘌呤但已停药>6个月的患者,AML/MDS风险未见显著增加,或可考虑停药后风险回落。
局限性
- 研究基于退伍军人事务数据集,可能影响结果外推性。
- 回顾性设计可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are rare myeloid clonal disorders that commonly affect the elderly population and have poor prognosis. There are limited data on the risk of AML/MDS among patients with inflammatory bowel disease (IBD), especially on the impact of thiopurines (TPs). METHODS: We conducted a retrospective cohort study among patients with IBD from Veteran Affairs data set. The exposure of interest was TP exposure: (i) never exposed to TPs, (ii) past TP use (discontinued >6 months ago), (iii) current TP use with a cumulative exposure of <2 years, and (iv) current TP use with a cumulative exposure of ≥2 years. The outcome of interest was a composite outcome of incident diagnosis of AML and/or MDS. Cox regression was used to estimate the adjusted and unadjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for AML/MDS risk associated with TP use defined as a time-varying exposure. RESULTS: Among 56,314 study patients, 107 developed AML/MDS. The overall incidence of AML/MDS in the IBD population was 18.7 per 100,000 patient-years. The incidences among those never exposed to TPs, past users of TPs, current users of TPs with a cumulative exposure of <2 years, and current users of TPs with a cumulative exposure of ≥2 years were 17.0, 17.7, 30.4, and 30.3 per 100,000 patient-years, respectively. In multivariable Cox regression analysis, compared with never exposed to TPs, current use of TPs was associated with increased risk (adjusted HR 3.05; 95% CI 1.54-6.06, P = 0.0014 for current use of TPs with a cumulative exposure of <2 years and adjusted HR 2.32; 95% CI 1.22-4.41, P = 0.0101 for current use of TPs with a cumulative exposure of ≥2 years), whereas past TP exposure was not. DISCUSSION: Among patients with IBD, current TP use was associated with an increased risk of AML/MDS, which reverts to baseline after discontinuation of TP use.
引用
- Khan N, Patel D, Trivedi C, et al. Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk. Am J Gastroenterol. 2021. PMID: 33982944. doi:10.14309/ajg.0000000000001058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。